StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BMO on Eli Lilly (LLY): 'Triple Agonist Turns Double Play - Extending Positive Results to Both T2D and OA'
March 19, 2026 10:17 AM
BMO Capital analyst Evan Seigerman reiterated an Outperform rating and $1,300.00 price target on Eli Lilly (NYSE: LLY).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
